Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Abciximab has been demonstrated to improve outcome when administered during primary
angioplasty in patients with acute myocardial infarction. The Primary Objective of the study
is to demonstrate that early (before transportation form remote hospital to the cath lab)
abciximab administration during acute myocardial infarction reduces infarct size as compared
with late (just prior to PCI) abciximab administration, as measured by delayed enhancement
magnetic resonance (MR) at 6 months.
Phase:
Phase 4
Details
Lead Sponsor:
University of Pisa
Collaborator:
Eli Lilly and Company
Treatments:
Abciximab Antibodies, Monoclonal Immunoglobulin Fab Fragments